Browse > Article
http://dx.doi.org/10.4333/KPS.2010.40.5.269

Screening for Chemosensitizers from Natural Plant Extracts through the Inhibition Mechanism of P-glycoprotein  

Ahn, Hee-Jeong (Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine)
Song, Im-Sook (Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine)
Publication Information
Journal of Pharmaceutical Investigation / v.40, no.5, 2010 , pp. 269-275 More about this Journal
Abstract
P-gp plays a critical role in drug disposition and represents a mechanism for the development of multidrug resistance. Flavonoids, a major class of natural compounds widely present in foods and herbal products, have been shown to inhibit P-gp. Therefore, the aim of this study was to identify new candidate chemosensitizers by screening various plant extracts. The ability of natural plant extracts to inhibit P-gp activity was assessed by measuring cellular accumulation of calcein AM, daunorubicin and vincristine in P-gp overexpressing MDCKII-MDR1 cells. Among more than 800 plant extracts, eight were found to inhibit P-gp activity. Curcuma aromatica extract produced greatest inhibition, followed by Curcuma longa and Dalbergia odorifera extracts. Extracts of Aloe ferox, Curcuma zedoariae rhizome, Zanthoxylum planispinum, and Ageratum conyzoides showed moderate inhibitory effects. Curcumin and quercetin exhibited similar inhibition of P-gpmediated efflux of daunorubicin and vincristine, and flavones had a lesser effect. When chemosensitizing effect was evaluated by measuring daunorubicin sensitivity to MDCKII-MDR1 cells in the presence of natural plant extracts, Curcuma aromatica showed the most potent chemosensitizing effect based on daunorubicin cytotoxicity. In conclusion, natural plant extracts such as Curcuma aromatica can potently inhibit P-gp activity and may have potential as a novel chemosensitizers.
Keywords
Natural plant extracts; Curcuma aromatica; P-gp inhibitors; Chemosensitizer;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Liow, J.S., Lu, S., McCarron, J.A., Hong, J., Musachio, J.L., Pike, V.W., Innis, R.B., Zoghbi, S.S., 2007. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)- (-)-RWAY. Synapse 61, 96-105.   DOI
2 Liscovitch, M., Lavie, Y., 2002. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5, 349-355.
3 Marchetti, S., Mazzanti, R., Beijnen, J.H., Schellens, J.H., 2007. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 12, 927-941.   DOI
4 Muzi, M., Mankoff, D.A., Link, J.M., Shoner, S., Collier, A.C., Sasongko, L., Unadkat, J.D., 2009. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J. Nucl. Med. 50, 1267- 1275.   DOI
5 Ozben, T., 2006. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580, 2903-2909.   DOI
6 Pilarski, L.M., Yatscoff, R.W., Murphy, G.F., Belch, A.R., 1998. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers. Leukemia 12, 505-509.   DOI
7 Renes, J., de Vries, E.G., Nienhuis, E.F., Jansen, P.L., Muller, M., 1999. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. 126, 681-688.   DOI
8 Shin, S.C., Choi, J.S., Li, X., 2006. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int. J. Pharm. 313, 144-149.   DOI
9 Tan, B., Piwnica-Worms, D., Ratner, L., 2000. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 12, 450-458.   DOI
10 Deng, S.G., Wu, Z.F., Li, W.Y., Yang, Z.G., Chang, G., Meng, F.Z., Mo, L.L., 2004. Safety of Curcuma aromatica oil gelatin microspheres administered via hepatic artery. World J. Gastroenterol. 10, 2637-2642.   DOI
11 Efferth, T., Davey, M., Olbrich, A., Rucker, G., Gebhart, E., Davey, R., 2002. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug- resistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis. 28, 160-168.   DOI
12 Essodaigui, M., Broxterman, H.J., Garnier-Suillerot, A., 1998. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 37, 2243-2250.   DOI
13 Fawole, O.A., Amoo, S.O., Ndhlala, A.R., Light, M.E., Finnie, J. F., Van Staden, J., 2010. Anti-inflammatory, anticholinesterase, antioxidant and phytochemical properties of medicinal plants used for pain-related ailments in South Africa. J. Ethnopharmacol. 127, 235-241.   DOI
14 Havsteen, B.H., 2002. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 96, 67-202.   DOI
15 Krishna, R., Mayer, L.D., 2000. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283.   DOI
16 Lee, J.S., Kim, D.H., Liu, K.H., Oh, T.K., Lee, C.H., 2005. Identification of flavonoids using liquid chromatography with electrospray ionization and ion trap tandem mass spectrometry with an MS/MS library. Rapid Commun. Mass Spectrom. 19, 3539-3548.   DOI
17 Versantvoort, C.H., Broxterman, H.J., Lankelma, J., Feller, N., Pinedo, H.M., 1994. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem Pharmacol. 48, 1129-1136.   DOI
18 Deferme, S., Augustijns, P., 2003. The effect of food components on the absorption of P-gp substrates: a review. J. Pharm. Pharmacol. 55, 153-162.   DOI
19 Deferme, S., Van Gelder, J., Augustijns, P., 2002. Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an invitro screening. J. Pharm. Pharmacol. 54, 1213-1219.   DOI
20 Thomas, H., Coley, H.M., 2003. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159-165.   DOI
21 Wu, W.Y., Xu, Q., Shi, L.C., Zhang, W.B., 2000. Inhibitory effects of Curcuma aromatica oil on proliferation of hepatoma in mice. World J. Gastroenterol. 6, 216-219.
22 Zhang, S., Yang, X., Morris, M.E., 2004. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 65, 1208-1216.   DOI
23 Zhou, S., Lim, L.Y., Chowbay, B., 2004. Herbal modulation of Pglycoprotein. Drug Metab. Rev. 36, 57-104.   DOI
24 Bailey, D.G., Spence, J.D., Munoz, C., Arnold, J.M., 1991. Interaction of citrus juices with felodipine and nifedipine. Lancet 337, 268-269.   DOI
25 Li, Y., Wo, J.M., Liu, Q., Li, X., Martin, R.C., 2009. Chemoprotective effects of Curcuma aromatica on esophageal carcinogenesis. Ann. Surg. Oncol., 16 515-523.   DOI
26 Limtrakul, P., 2007. Curcumin as chemosensitizer. Adv. Exp. Med. Biol. 595, 269-300.   DOI
27 Ahn, H.J., Kim, J.Y., Lee, C.H., Song, I.S., Liu, K.H., 2008.Screening of chemosensitizer candidates using natural extracts. J. Life Sci. 18, 1244-1248.   DOI
28 Bansal, T., Jaggi, M., Khar, R.K., Talegaonkar, S., 2009. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci. 12, 46-78.   DOI
29 Choi, C.H., 2005. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5, 30.   DOI
30 Choi, J.S., Choi, H.K., Shin, S.C., 2004a. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int. J. Pharm. 275, 165-170.   DOI
31 Choi, J.S., Jo, B.W., Kim, Y.C., 2004b. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm. Biopharm. 57, 313-318.   DOI
32 Dantzig, A.H., de Alwis, D.P., Burgess, M., 2003. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev. 55, 133-150.   DOI